Vaccination News

Real-world data showed that bivalent messenger RNA vaccines against SARS-CoV-2 provided “significant additional protection” against symptomatic COVID-19 among people who had received two, three or four previous monovalent doses.

PHILADELPHIA — An initial double dose of pneumococcal vaccine improves immune response against pneumococcal pneumonia in patients with ANCA-associated vasculitis treated with rituximab, according to data presented at ACR Convergence 2022.

Data from a phase 2/3 trial showed that Moderna’s bivalent COVID-19 booster shot outperformed the company’s original vaccine against SARS-CoV-2 omicron subvariants.

A surge of respiratory syncytial virus, an early start to influenza season and the ongoing COVID-19 pandemic have caused a “tripledemic” in the United States, overwhelming hospitals, experts said.

NEW YORK — In this video from the Infectious Diseases in Children Symposium, Yvonne A. Maldonado, MD, discusses three emerging or reemerging infectious diseases: polio, monkeypox and highly pathogenic avian influenza virus.

NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, describes multiple interventions in development against respiratory syncytial virus, which is currently surging in the United States.

NEW YORK — It is hoped that the future of COVID-19 vaccines for children will include simplifying the process of getting shots into their arms, CDC medical officer Sara E. Oliver, MD, MSPH, says in this video.

The bivalent COVID-19 booster vaccine from Pfizer-BioNTech elicited a stronger response against the BQ.1.1 sublineage than the companies’ original vaccine in people aged 55 years and older, according to new data from the companies.

Novavax’s original COVID-19 vaccine and omicron subvariant vaccine candidate were both successful in a phase 3 trial, according to the company.

Moderna said Monday that data from a phase 2/3 trial showed that its bivalent COVID-19 booster shot triggers a higher antibody response against SARS-CoV-2 omicron subvariants than its original vaccine.